Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.46 |
| ▸ | ITGAL | P20701 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190928 | 1.00 | HCAR2 (0.48) | HCAR2HPGDITGB2ICAM1ITGAL | |
| SCHEMBL13636365 | 0.99 | HPGD (0.47) | HCAR2HPGDITGB2ICAM1ITGAL | |
| SCHEMBL4377227 | 0.99 | HPGD (0.47) | HCAR2HPGDITGB2ICAM1ITGAL | |
| SCHEMBL2833140 | 0.91 | HPGD (0.50) | HCAR2HPGDITGB2ICAM1ITGAL | |
| SCHEMBL3765820 | 0.89 | ITGB2 (0.42) | HCAR2HPGDITGB2ICAM1ITGAL | |
| SCHEMBL3765817 | 0.89 | ITGB2 (0.42) | HCAR2HPGDITGB2ICAM1ITGAL | |
| SCHEMBL14190925 | 0.85 | KMT2A (0.60) | HPGDKDM4EKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4386306 | 0.85 | KMT2A (0.60) | HPGDKDM4EKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4382984 | 0.84 | KMT2A (0.61) | HPGDKDM4EKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL14190940 | 0.84 | KMT2A (0.61) | HPGDKDM4EKMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | HCAR2 10/4885HPGD 646/4885ITGB2 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.